Flynpovi: Withdrawal of the marketing authorisation application

eflornithine / sulindac


Cancer Prevention Pharma (Ireland) Limited withdrew its application for a marketing authorisation of Flynpovi for the treatment of familial adenomatous polyposis.

The company withdrew the application on 12 October 2021.

  • List item

    Questions and answers on the withdrawal for the marketing authorisation of Flynpovi (eflornithine / sulindac) (PDF/122.98 KB)

    First published: 12/11/2021

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • eflornithine
    • sulindac
    Active substance
    • Eflornithine hydrochloride
    • Sulindac
    Date of withdrawal
    Company making the application
    Cancer Prevention Pharma (Ireland) Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating